Ibu-Lysin (Ibuprofen D,l-Lysinate)

Ibuprofen D,l‑lysinate non‑selectively blocks the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes. This inhibition reduces the synthesis of prostaglandins, the mediators responsible for pain, fever, and inflammation, thereby providing analgesic, antipyretic, and anti‑inflammatory effects.

The appropriate dose of Ibu-Lysin is determined by the prescribing healthcare professional based on the individual’s condition, age, weight, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Ibu-Lysin is classified as pregnancy category B, indicating no proven risk in animal studies, but it should be used only if clearly needed. It is generally avoided in the third trimester. Breastfeeding mothers should consult their physician, as ibuprofen can be excreted in breast milk.

To order Ibu-Lysin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Ibu-Lysin uses the lysine salt form of ibuprofen, which can improve solubility and may lead to faster absorption compared with standard ibuprofen tablets. Therapeutic effects are similar, but the lysinate formulation may offer a slightly different onset of action or tolerability profile.

Ibu-Lysin should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Ibu-Lysin is taken orally, usually with a glass of water. It can be taken with or without food, but taking it with food may reduce gastrointestinal discomfort. The exact administration schedule should follow the prescriber’s directions.

Serious risks include gastrointestinal bleeding or ulcer perforation, severe allergic reactions such as anaphylaxis, acute kidney injury, and rare but severe skin reactions like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience signs of these conditions.

Ibu-Lysin should be avoided by individuals with known hypersensitivity to ibuprofen or other NSAIDs, those with active gastrointestinal ulcers, severe heart failure, or severe renal impairment. It is also contraindicated in the third trimester of pregnancy and in patients taking certain anticoagulants without medical supervision.